Press Release: Curetis Publishes Business and Financial Update for the First Nine Months 2016
(Thomson Reuters ONE) -
Curetis /
Press Release: Curetis Publishes Business and Financial Update for the First
Nine Months 2016
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
- U.S. FDA trial completed with excellent top-line data
- Leading position in genetic antimicrobial resistance biomarker testing
strengthened by GEAR acquisition
Amsterdam, the Netherlands, and Holzgerlingen, Germany, November 18, 2016 -
Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a
developer of next-level molecular diagnostic solutions, today published a
business and financial update for the first nine months ended September
30, 2016 and provided an outlook to coming months.
Recent Operational and Business Highlights
Unyvero US FDA Trial
* Curetis successfully completed the U.S. FDA trial for the Unyvero Platform
and its LRT Application in lower respiratory tract infections and reported
positive top-line data in October 2016. The prospective and retrospective
study met its primary endpoint by demonstrating an overall weighted average
sensitivity of 90.2% and an overall average weighted specificity of 99.3%.
These data are fully consistent and in line with the performance evaluation
previously conducted by Curetis for CE IVD marking in Europe, as well as
published data from various European KOLs and customer sites.
* The submission of Curetis' (de novo) 510(k) data package to the U.S. FDA is
expected in due course. FDA feedback and the potential clearance for Unyvero
and start of commercialization are expected in the first half of 2017.
* Curetis is preparing to enter U.S. FDA trials for its next U.S. product. To
that end, the Company has submitted a so-called pre-submission package to
the FDA for a U.S. version of its Unyvero ITI Cartridge. Based on the FDA's
feedback and additional market research data that are expected in Q4-2016,
Curetis will determine appropriate next steps and timelines for a U.S. FDA
trial for this second product. Further details will be announced in 2017.
Acquisition of NGS Database GEAR and IP from Siemens
* Curetis has acquired sole commercial rights from Siemens Technology
Accelerator to the GEAR (GEnetic Antibiotic Resistance and Susceptibility)
platform and database with all its content, numerous GEAR-related patents
and patent applications, as well as all corresponding know-how. The deal
gives Curetis sole worldwide product development and commercial rights,
including the right to sublicense assets in human and animal diagnostics as
well as food safety testing. Furthermore, Curetis has secured the sole
rights to leverage the GEAR assets in collaboration with pharmaceutical
companies for the development of novel antimicrobial drugs for human and
animal health.
* The state-of-the-art bioinformatics database comprises more than 11,300
bacterial strains that have been collected at more than 200 sites on 5
continents over 30 years. The next gene sequencing (NGS) data with 0.4
trillion reads is a wealth of comprehensive and internationally relevant
information amounting to 30 terabytes in total.
* GEAR allows Curetis to rapidly identify potential novel biomarkers,
biomarker combinations, and algorithms predicting antibiotic resistance, as
well as potential novel targets for antimicrobial drugs. The acquisition of
the GEAR database and patent estate adds significantly to the leading
position that Curetis has established in the area of genetic antimicrobial
resistance biomarker testing with its Unyvero Cartridges. Curetis intends to
further expand and mine the GEAR database in collaboration with leading
academic institutions as well as pharmaceutical and diagnostics companies
and leverage those into commercial products on its Unyvero Molecular
Diagnostics platform and beyond.
Commercial Expansion
* United States
Following the appointment of Christopher M. Bernard as President and Chief
Executive Officer of Curetis USA, Inc. in La Jolla, San Diego, CA, the Company
has been building its senior leadership and U.S. commercial core team for the
North American market during the second half of 2016. The U.S. subsidiary has
been founded to drive the future commercial development and sales of the
Company's Unyvero Platform in North America. Curetis is planning direct
commercialization of all Unyvero Products in the U.S. hospital market.
* Europe
The Company has made excellent progress in expanding its commercial footprint in
its direct sales territories. To this end, Curetis has established four new
wholly owned commercial subsidiaries in Europe covering the UK, the Netherlands
for the Benelux area, France and Switzerland and has hired senior market
development managers and key account managers from industry leaders such as
Roche, Cepheid, Abbott and others.
Product Development
* After launching the BCU Blood Culture Application Cartridge in Q2-2016,
Curetis has launched its second Unyvero Test this year with its next
generation Unyvero ITI Cartridge for Implant and Tissue Infections in
September 2016. The CE performance evaluation study was successfully
completed and demonstrated an overall average sensitivity for all pathogens
of 86.9% and an overall average specificity for all pathogens of 99.2% in a
total of 1,100 samples. The next-generation cartridge now covers a total of
102 (up from 80 in first generation) diagnostic targets: 85 of the most
clinically relevant pathogenic microorganisms, including Gram positive and
Gram negative bacteria, several fungi, and 17 related antibiotic resistance
markers.
* The Company has furthermore progressed the development of the IAI Intra-
Abdominal Infection Cartridge, its fourth Unyvero Application, towards
completion by the end of this year. In addition, the partnered Sepsis Host
Response program (anticipated completion not before the end of 2017) is
progressing according to plan.
Installed Base
* Curetis has continued to expand the installed base of Unyvero Analyzers to
121 as of September 30, 2016 (vs. 79 instruments as of September 30, 2015,
i.e. an increase by 53% year over year).
Financial Highlights for the First Nine Months 2016
* Revenues: EUR 1.1 million (vs. EUR 0.9 million in the nine months ended
September 30, 2015). Overall revenues were up by 21.7% year over year. While
revenues in the first half of 2015 had included EUR 297 thousand generated
by Unyvero Systems sales to a pharma partner, revenues in the same period in
2016 did not include any such system sales to pharma. In general, revenues
are expected to remain volatile from quarter-to-quarter, as early-stage
instrument sales to distribution partners are unevenly spread throughout the
year.
* Expenses: EUR 12.0 million (vs. EUR 9.6 million in the nine months ended
September 30, 2015). The increase is in line with the operational and
organizational growth strategy and driven by higher R&D expenses,
distribution costs as well as G&A costs.
* Gross loss: EUR 0.1 million (vs. a gross loss of EUR 0.5 million in the nine
months ended September 30, 2015). The relatively low gross margin is
significantly impacted by the mix of systems sales to cartridge sales and by
IFRS accounting requiring excess capacity of the cartridge manufacturing
line and facility to be allocated to actual period cartridge output.
* Net loss: EUR 10.7 million (vs. a profit of EUR 13.5 million in the nine
months ended September 30, 2015). The profit in the nine months ended
September 30, 2015 was due to 23.6 million financial income resulting from a
one-time accounting-effect due to the revaluation of preferred and common
shares under IFRS.
* Cash and cash equivalents: A strong cash position of EUR 35.4 million as of
September 30, 2016 (vs. EUR 46.1 million as of December 31, 2015) and a net
cash burn of 10.6 EUR million during the nine months of 2016 for all
operating, investment and financing activities combined.
Key non-audited financials as of September 30, 2016
+----------------------------+------------------------+------------------------+
|Curetis N.V. | | |
+----------------------------+------------------------+------------------------+
|consolidated numbers in '000| | |
|Euros | | |
+----------------------------+------------------------+------------------------+
| | |For the nine months |
| |For the nine months |ended September |
| |ended September 30, 2016|30, 2015 |
+----------------------------+------------------------+------------------------+
|Revenues | 1,077| 885|
+----------------------------+------------------------+------------------------+
|Operating loss | (10,760)| (8,676)|
+----------------------------+------------------------+------------------------+
|Total comprehensive income | (10,731)| 13,493|
+----------------------------+------------------------+------------------------+
| | | |
+----------------------------+------------------------+------------------------+
| |September 30, 2016 |December 31 2015 |
+----------------------------+------------------------+------------------------+
|Cash and cash equivalents | 35,415| 46,060|
+----------------------------+------------------------+------------------------+
Comparative figures for the nine months ended September 30, 2015, are those of
Curetis GmbH (former AG).
"We are very happy with the operational development," said Dr. Oliver Schacht,
CEO of Curetis. "We completed the U.S. FDA study on time and as planned. We are
now using the outcome, a very strong and comprehensive data set, for compiling
the final submission documents and look forward to receiving feedback from the
FDA. In addition, we launched the next-generation Unyvero ITI Cartridge for
Implant and Tissue Infections and submitted the pre-submission package to the
FDA for a U.S. version of the Unyvero ITI Cartridge."
"Furthermore, the GEAR acquisition allows us to significantly expand the scale
and scope of the Unyvero Platform and complement it with NGS-based knowledge,"
he added. "GEAR will allow us to stay on top of the development of cutting-edge
molecular diagnostic products for critical hospital infections as it will serve
as an engine for even more comprehensive and differentiated content of
antibiotic resistance biomarkers in our Unyvero Products. Last but not least,
the commercial expansion is also progressing in both Europe and the U.S., where
we have built a senior leadership and U.S. commercial core team for the North
American market."
###
Disclaimer
CAUTION - Investigational device. Limited by Federal (or United States) law to
investigational use. The information contained in this communication does not
constitute nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for sale in the
United States of America or Canada. The analytical and clinical performance
characteristics of any Curetis Unyvero product which may be sold at some future
point in time in the U.S. have not yet been established.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million. The company
is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed
collaboration agreements with Heraeus Medical and Cempra Inc. as well as several
international distribution agreements covering many countries across Europe, the
Middle East and Asia.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info((at))akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
20161118_Curetis_PR_EN:
http://hugin.info/171382/R/2057877/771146.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Curetis via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 18.11.2016 - 07:31 Uhr
Sprache: Deutsch
News-ID 507960
Anzahl Zeichen: 16910
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 340 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Press Release: Curetis Publishes Business and Financial Update for the First Nine Months 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
